Safety of biological and targeted synthetic disease-modifying antirheumatic drugs for rheumatoid arthritis as used in clinical practice: results from the Anti-Rheumatic Therapies in Sweden (ARTIS) programme
Authors' conclusion
Data from ARTIS supports that the b/tsDMARDs currently used to treat RA have acceptable and largely similar safety profiles, but differences exist in particular concerning tolerability and specific infection risks.
Study context
- Population
- All patients with rheumatoid arthritis (RA) in Sweden starting any b/tsDMARD 1 January 2010 through 31 December 2020, followed until 30 June 2021 (ARTIS)
- Participants
- 20,117 patients
- Exposure
- Individual b/tsDMARDs compared with each other
- Outcome
- Incidence rates of key safety outcomes, identified through national healthcare registers
Methodological detailsadjusted for demographics, RA disease characteristics and comorbidity
- Adjusted for demographics, RA disease characteristics and comorbidity
Main finding
As reported in the abstract
Hospital-treated herpes zoster
Each group vs etanerceptHazard ratio (95% CI)
Baricitinib
3.82(2.05–7.09)
Tofacitinib
4.00(1.59–10.06)
Observational data: associations, not effects.
Safety
Treatment discontinuations due to adverse events, rate per 1000 person-years
Treatment discontinuations due to adverse events, rate per 1000 person-years
- Marked differences between drugs (range 18 on rituximab to 57 on tofacitinib)
Original publication
Safety of biological and targeted synthetic disease-modifying antirheumatic drugs for rheumatoid arthritis as used in clinical practice: results from the ARTIS programme. Ann Rheum Dis. Published 14 February 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →